Orphalan Makes History as First European Company to Enter China's Wilson Disease Market with "Ke Pei Ou"
• Orphalan has launched trientine tetrahydrochloride ("Ke Pei Ou") in China through a strategic partnership with SPH Kyuan Trade, becoming the first European company to introduce an orphan drug for Wilson disease in this market.
• The treatment addresses a critical unmet need for Chinese Wilson disease patients who cannot tolerate penicillamine, the previous standard therapy, offering an alternative that is already available in over 20 countries globally.
• Orphalan has established a local entity in Shanghai led by Grace Li as General Manager, demonstrating its commitment to ensuring Chinese patients and healthcare providers have access to advanced Wilson disease treatment options.
© Copyright 2025. All Rights Reserved by MedPath